David B. Singer - 17 Feb 2022 Form 4 Insider Report for CASTLIGHT HEALTH, INC.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
18 Feb 2022, 13:12:18 UTC
Prior SEC filing
19 Jul 2021
Next SEC filing
18 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Mary Ahern, as attorney-in-fact

Key filing fact

David B. Singer filed Form 4 for CASTLIGHT HEALTH, INC. on 18 Feb 2022.

Key facts

  • This page summarizes David B. Singer's Form 4 filing for CASTLIGHT HEALTH, INC..
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 18 Feb 2022, 13:12.

Change

  • Previous filing in this sequence was filed on 19 Jul 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CSLT transaction

Class B Common Stock

Disposed to Issuer

Transaction value
Shares
-405,184
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CSLT transaction Derivative

Director Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-25,000
Change %
-100%
Price
Shares after
0
Date
17 Feb 2022
Ownership
Direct
Underlying class
Class B Common Stock
Underlying amount
25,000
Exercise price
$16.00
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

David B. Singer is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 4, 2022, by and among the Issuer, Vera Whole Health, Inc. ("Vera Health"), and Carbon Merger Sub, Inc. (the "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Vera Health, effective as of February 17, 2022 (the "Effective Time"). Pursuant to the Merger Agreement, each share of the Issuer's Class A common stock and Class B common stock was exchanged for $2.05 in cash (the "Merger Consideration") at the Effective Time.

Footnote F2

The option is fully vested and exercisable.

Footnote F3

The option exercise price is equal to or exceeds the Merger Consideration and therefore the option was automatically cancelled without consideration immediately prior to the Effective Time.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .